Skip to main content
Clinical Trials/CTRI/2024/02/062960
CTRI/2024/02/062960
Not yet recruiting
未知

Myocardial deformation imaging to assess subclinical myocardial dysfunction in patients with metabolic dysfunction associated steatotic liver disease(MASLD) and its correlation with liver stiffness measurement. - NI

Kasturba Medical College Manipal0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: K740- Hepatic fibrosis
Sponsor
Kasturba Medical College Manipal
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational

Investigators

Eligibility Criteria

Inclusion Criteria

  • Metabolic dysfunction associated steatotic liver disease(MASLD) defined as presence of hepatic steatosis by imaging(USG )or biopsy with atleast one of the cardiometabolic criteria which includes
  • BMI more than 25 kg/m2 or WC more than 94 cm in males or 80 cm in
  • FBS more than 100, PPBS more than 200,HBA1C more than 5\.7 or known case of T2DM
  • BP more than 130/85mmhg
  • Plasma triglyceride more than 170 mg/dl
  • Plasma HDL less than 40mg/dl in males HDL less than 50mg/dl in females
  • Age less than 65 years and more than 18 years
  • Average daily alcohol intake less than 20g/day female, less than 40gm/day in males

Exclusion Criteria

  • age more than 65 years and less than 18 years
  • daily alcohol intake on more than 20g/day in female, more than 40g/day in male
  • diagnosis of cirrhosis at histology or at clinical ground
  • presence of hepatocellular carcinoma, ascites, portal hypertension; other comorbid liver diseases (autoimmune hepatitis, HBV, HCV, alcoholic liver disease)
  • atrial fibrillation; left bundle branch block; history of coronary artery disease (previous myocardial infarction, previous percutaneous coronary intervention or previous coronary artery bypass graft)
  • moderate\-to\-severe mitral and/or aortic valve disease; hypertrophic, infiltrative and/or dilated cardiomyopathy
  • history of congenital heart disease
  • left ventricular ejection fraction (LVEF)less than 50%
  • acute coronary syndrome, acute congestive heart failure, acute respiratory failure, acute renal failure
  • hemodynamic instability

Outcomes

Primary Outcomes

Not specified

Similar Trials